UK House Prices in Surprise Increase; NatWest Braces for Slowing Economy – Business Live

Why It Matters

The housing data signals lingering demand that could soften forecasts of a UK market slowdown, NatWest’s earnings underscore banking sector resilience, and the tariff cut revitalises UK export competitiveness.

Key Takeaways

• Nationwide house price index rose 0.4% in April, hitting £278,880 ($354k).
• NatWest Q1 profit hit £1.4bn ($1.78bn) despite economic gloom.
• Diageo shares climbed 2% after Trump lifted 10% whisky tariffs.
• AstraZeneca fell 1.9% after FDA panel rejected camizestrant.
• Mortgage‑rate outlook may curb future UK house‑price gains.

Pulse Analysis

The latest Nationwide data surprised analysts by showing a 0.4% month‑on‑month rise in UK house prices, lifting the average to £278,880 (roughly $354,000) and nudging annual growth to 3.0%. This resilience comes amid heightened geopolitical risk from the Iran‑related conflict and a dip in consumer‑confidence indices, suggesting that underlying demand—driven by limited supply and continued buyer activity—remains robust. For investors, the figure challenges the narrative of an imminent housing‑market correction and may influence mortgage‑lending strategies as banks reassess credit risk.

NatWest’s first‑quarter results added another layer to the UK financial landscape. The bank posted a headline profit of £1.4 bn ($1.78 bn) and raised its 2026 income outlook to the top of the £17.2‑£17.6 bn band, yet its shares slipped 3.7% after analysts stripped out one‑off items and found underlying earnings slightly weaker than expected. The performance highlights how AI‑driven productivity gains and diversified retail‑banking revenue can offset a softer macro environment, but it also underscores the market’s sensitivity to guidance gaps. Stakeholders will watch NatWest’s balance‑sheet provisioning and its ability to sustain growth as mortgage rates climb.

On the trade front, Diageo’s 2% share‑price rise reflects the market’s positive reaction to President Trump’s decision to eliminate a 10% tariff on Scotch whisky, effectively turning a $1.27‑per‑pound cost advantage into a direct boost for UK exporters. The move not only benefits Diageo’s premium portfolio—Johnnie Walker, Lagavulin, and others—but also signals a broader willingness for the United States to ease barriers on British goods, potentially revitalising other sectors such as automotive and pharmaceuticals. Conversely, AstraZeneca’s 1.9% dip after an FDA advisory committee voted against its new breast‑cancer therapy underscores the volatility that regulatory outcomes can inject into biotech valuations, reminding investors that drug‑development pipelines remain a high‑risk, high‑reward arena.